Compounds > topotecan
Page last updated: 2024-08-24

topotecan and nutlin-3a

topotecan has been researched along with nutlin-3a in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ayrault, O; Roussel, MF; Zindy, F1
Dalgard, CL; deNiro, JE; Gonzalez, M; O'Brien, JM1
Dudgeon, DD; Giuliano, KA; Johnston, PA; Lazo, JS; Shinde, SN; Shun, TY; Strock, CJ; Taylor, DL1
de Lange, J; Jager, MJ; Jochemsen, AG; Lodder, K; Ly, LV; Teunisse, AF; Verlaan-de Vries, M1
Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M1

Other Studies

5 other study(ies) available for topotecan and nutlin-3a

ArticleYear
[TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].
    Medecine sciences : M/S, 2007, Volume: 23, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Transformation, Neoplastic; Cellular Senescence; Cyclin D; Cyclin-Dependent Kinases; Cyclins; DNA Damage; Eye Neoplasms; Genes, p16; Genes, p53; Genes, Retinoblastoma; Humans; Imidazoles; Mice; Models, Biological; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma; Retinoblastoma Protein; Topotecan; Tumor Suppressor Protein p14ARF; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2007
Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.
    Investigative ophthalmology & visual science, 2009, Volume: 50, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Cell Survival; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; MicroRNAs; Piperazines; Retinal Neoplasms; Retinoblastoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2009
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
    Assay and drug development technologies, 2010, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Biosensing Techniques; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 2; Ellipticines; Genes, p53; High-Throughput Screening Assays; Humans; Imidazoles; Mitoxantrone; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Small Molecule Libraries; Spectrometry, Fluorescence; Topotecan; Tumor Suppressor Protein p53

2010
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
    Oncogene, 2012, Mar-01, Volume: 31, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Synergism; Furans; Humans; Hypoxia; Imidazoles; Melanoma; Melanoma, Experimental; Mice; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Topotecan; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uveal Neoplasms

2012
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
    The Journal of pharmacy and pharmacology, 2016, Volume: 68, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea

2016